Marker Therapeutics (MRKR) Assets Average (2011 - 2026)

Marker Therapeutics (MRKR) has reported Assets Average for 16 consecutive years, with $16.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average rose 0.81% year-over-year to $16.0 million in Q2 2026; TTM through Jun 2026 was $16.0 million, a 0.81% increase from a year earlier, with the FY2025 full-year figure at $20.5 million, up 4.96% from the prior year.
• Assets Average was $16.0 million for Q2 2026 at Marker Therapeutics, down from $18.3 million in the prior quarter.
• Over five years, Assets Average peaked at $61.5 million in Q1 2022 and troughed at $11.3 million in Q3 2024.
• A 5-year average of $25.5 million and a median of $18.9 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average slumped 55.65% in 2023 and surged 61.62% in 2025, its largest moves.
• Over 5 years, Assets Average stood at $37.8 million in 2022, then slumped by 51.53% to $18.3 million in 2023, then fell by 10.05% to $16.5 million in 2024, then climbed by 23.9% to $20.4 million in 2025, then slipped by 21.53% to $16.0 million in 2026.
• The last three Assets Average figures came in at $16.0 million (Q2 2026), $18.3 million (Q1 2026), and $20.4 million (Q4 2025), per Business Quant data.